C38 UNDERSTANDING THERAPEUTICS IN IPF: Effect Of Pirfenidone On A Novel Definition Of Progression-Free Survival (pfs) In Patients With Idiopathic Pulmonary Fibrosis (ipf): Pooled Analysis From Phase Iii Trials

The novel definition of PFS was time to the first occurrence of a respiratory-related hospitalization (determined by adverse event report), > 10% absolute decline from baseline in FVC or death. The novel PFS definition resulted in a hazard ratio in favor of pirfenidone of 0.49 (95% CI, 0.38, 0.64...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of respiratory and critical care medicine Vol. 195
Main Authors Lederer, D J, Trzaskoma, B L, Kirchgassler, K-U, Kreuter, M, Swigris, J J
Format Journal Article
LanguageEnglish
Published New York American Thoracic Society 01.01.2017
Subjects
Expected values
Hospitalization
Pulmonary fibrosis
Online AccessGet full text

Cover

More Information
Summary:The novel definition of PFS was time to the first occurrence of a respiratory-related hospitalization (determined by adverse event report), > 10% absolute decline from baseline in FVC or death. The novel PFS definition resulted in a hazard ratio in favor of pirfenidone of 0.49 (95% CI, 0.38, 0.64; P < 0.0001; Figure) compared with the pre-specified PFS definition (0.62; 95% CI, 0.51,0.75; P < 0.0001), indicating a greater relative risk reduction with pirfenidone compared with placebo.
ISSN:1073-449X
1535-4970